GlaxoSmithKline to drop quarterly results as Elliot presence signals it’s time for change
JP Morgan expect revenue to slide 11% to £7.7bn after the rollout of Shingrix was hindered by the pandemic
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 17 of 38
GlaxoSmithKline receives US approval for endometrial cancer treatment
The trial showed an overall response rate of 42.3% and a duration of response of six months or more for 93.3% of participants
GlaxoSmithKline biopharma spinoff to deliver solid sales growth contrary to market scepticism, says City broker
Liberum expects a spike in revenue after short-term headwinds this and next year
GlaxoSmithKline shares rally on report activist Elliot has stake
The activist fund manager has acquired what was described as a significant stake,
GlaxoSmithKline to help produce 60mln Novavax soon-to-be approved COVID-19 vaccine doses in UK plant
Novavax is expecting a decision from the regulator as soon as next month
GlaxoSmithKline dismisses former US vaccine executive from board of investee over sexual harassment allegations
The inappropriate conduct would have happened while Moncef Slaoui was still working at the pharma giant
GlaxoSmithKline starts fast-track coronavirus vaccine trial with Medicago
Medicago's candidate, in combination with Glaxo's pandemic adjuvant, has been granted Fast Track designation by the FDA
GlaxoSmithKline recommended to stop COVID-19 treatment trials early because of high efficacy
The pharma giant is developing a monoclonal antibody with US biotech Vir
GlaxoSmithKline tweaks COVID-19 treatment study after missing primary goal
The pharma giant is expanding the study to focus on the candidate's effects on patients aged over 70
GlaxoSmithKline and Sanofi to push ahead with phase II trial of Covid-19 vaccine
“We are confident that our vaccine candidate has strong potential and we are very encouraged by the latest preclinical data"
DNA testing company 23andMe to float using Richard Branson's cash shell
Previous backers include GlaxoSmithKline, which invested US$300mln in 2018 as part of an exclusive four-year collaboration deal
GlaxoSmithKline downgraded to ‘sell’ by Deutsche Bank after results worse than expected
Analysts remain cautious on the forecast growth rebound in 2022 because of COVID-19 disruption
TEST AUTOTAGGING - FTSE 100 dips into the red; Wall Street opens on a mixed footing following US jobs data
FTSE 100 index falls 10 pointsUS stocks start mixedUS private sector adds 174k jobs in January2.47pm: Mixed start for US stocksThe Wednesday session on Wall Street was off to a mixed start on Wednesday as investors digested the latest set o
GlaxoSmithKline expects more disruption in vaccines arm this year as governments focus on COVID-19
The firm is missing out on huge revenue upside from COVID-19 vaccines as it's months behind its competitors
GlaxoSmithKline enters €150mln collaboration with CureVac for COVID-19 vaccines
The pair will work on new jabs targeting new variants of the virus
Glaxo, Vodafone updates punctuate mid-week, US earnings eyed from Spotify and Qualcomm
Wednesday is scheduled to bring heavyweight updates from both sides of the Atlantic, while the macro diary is scheduled to see new PMI data from the UK and US service sectors
GlaxoSmithKline says ViiV receives US FDA approval for long-acting HIV regimen
Cabenuva reduces the treatment dosing days from 365 days to 12 days per year
GSK will need to cut its dividend, warns Credit Suisse
Meanwhile, another broker has Glaxo as its top pick in a pharma sector that looks poised for growth
GlaxoSmithKline-owned ViiV Healthcare receives green light for long-acting HIV treatment
ViiV’s Vocabria used in combination with Janssen Pharmaceutical’s rilpivirine injection and tablets
GlaxoSmithKline: Back to the drawing board for UK drugs giant and French partner in their bid to deliver coronavirus vaccine
It is the first setback in a largely successful quest for a vaccine